TSRO
Tesaro, Inc.
NasdaqGS
People also watch:CLVSPTLAEPZMPTCTXLRN
90.05-0.97 (-1.07%)

After hours: 90.050.00 (0.00%) as of 5:18 PM EDT

Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close91.02
Open0.00
Bid87.02 x 100
Ask98.58 x 200
52wk Range29.51 - 94.01
Day's Range88.17 - 90.65
Volume693,225
Avg Vol (3m)1,143,352
As of 4:00 PM EDT. Market closed.
  • Barrons.com5 days ago

    Gilead Has a Problem. These Three Biotechs Could Be the Solution

    Guggenheim's Tony Butler and Kaitlin Sandor argue that Gilead Sciences (GILD) should buy Syndax Pharmaceuticals (SNDX), Corvus Pharmaceuticals (CRVS), and Tesaro (TSRO) to solve its problem of slowing sales: ...[When] looking at consensus estimates through 2020, there is a slight, though continuous, decline in overall revenue with EPS remaining largely flat, likely due to share repurchases. With approximately $16 billion in operating cash flow annually and more than $21 billion in cash and short-term assets on the balance sheet, Gilead has a good deal of capital to deploy to boost its revenues. Most questions we receive on Gilead regard what should it “buy.” What type of business development activity should Gilead engage in that will support possibly higher future revenues?

  • Kiplinger12 days ago

    10 Stocks That Could Ruin Your Retirement

    Many of these stocks don't belong with other retirement holdings simply because the risk is too high.